Compare Pfizer Inc (PFE) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs State Street PDR S&P Retail ETF — how do they compare? Pfizer Inc trades at $27.83 (market cap $159.59B), while State Street PDR S&P Retail ETF trades at $86.52 (market cap $402.57M). The key difference: Pfizer Inc is far larger — about 396.4× State Street PDR S&P Retail ETF's market cap, and Pfizer Inc pays a 6.14% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| PFE | XRT | |
|---|---|---|
Market Cap | $159.59B | $402.57M |
Volume | 30,937,010 | 2,586,736 |
Sector | Health | Broad Market / Factor |
52-Week High | $29.02 | $92.35 |
52-Week Low | $23.67 | $77.28 |
Typical Hold Time | 158 Days | 44 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
XRT, the SPDR S&P Retail ETF, trades at $82.91, down 0.05% on the day, with a bearish technical signal from moving averages. The ETF faces headwinds from higher interest rates and inflation pressuring consumer spending, as reflected in mixed retail sales data. Recent news highlights holiday sales projections exceeding $1 trillion but also notes analyst expectations of underperformance versus the S&P 500 into 2027.
The outlook for XRT is cautious due to macroeconomic pressures on retail, though potential Fed easing could offer relief. Risks include consumer sentiment volatility and competitive shifts. Analyst sentiment is neutral to bearish, with institutional interest shown via options activity but no strong bullish consensus for near-term outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
